Nanterinone

CAS No. 102791-47-9

Nanterinone( —— )

Catalog No. M34663 CAS No. 102791-47-9

Nanterinone (UK 61260), an orally available partial phosphodiesterase inhibitor, is a novel positive inotropic and balanced vasodilator compound.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 342 In Stock
10MG 504 In Stock
25MG 816 In Stock
50MG 1097 In Stock
100MG 1479 In Stock
200MG Get Quote In Stock
500MG 2967 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Nanterinone
  • Note
    Research use only, not for human use.
  • Brief Description
    Nanterinone (UK 61260), an orally available partial phosphodiesterase inhibitor, is a novel positive inotropic and balanced vasodilator compound.
  • Description
    Nanterinone (UK 61260) is a positive inotropic and arterial vasodilating agent. Nanterinone is a phosphodiesterase inhibitor.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    PDE
  • Recptor
    PDE
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    102791-47-9
  • Formula Weight
    253.3
  • Molecular Formula
    C15H15N3O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CC=1N(C=C(C)N1)C=2C=C3C(=C(C)C2)NC(=O)C=C3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Remme WJ, et al. Acute hemodynamic effects and preload-dependent cardiovascular profile of the partial phosphodiesterase inhibitor nanterinone in patients with mild to moderate heart failure. Cardiovasc Drugs Ther. 1996 May;10(2):137-44.?
molnova catalog
related products
  • SEP-0372814

    SEP-0372814 is a potent inhibitor of PDE10.

  • TPN171

    TPN171 is potent PDE5 inhibitor with subnanomolar potency for PDE5 and good selectivity over PDE6, which has the potential for the treatment of pulmonary arterial hypertension (PAH).

  • Difamilast

    Difamilast (OPA-15406) is a novel potent, selective phosphodiesterase IV (PDE4) inhibitor with preference for PDE4B (IC50=11.2 nM).?